Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Tokyo Medical University enters RA research collaboration with Progenra

Progenra, Inc. announced today it has entered in to a research collaboration with Dr. Toshihiro Nakajima, Professor, Institute of Medical Science, Tokyo Medical University.

24 Oct 2011

Xencor commences XmAb5871 Phase 1 trial in autoimmune diseases

Xencor, Inc., a company using its proprietary Protein Design Automation (PDA) platform technology to engineer next-generation antibodies, announced today the initiation of a Phase 1 clinical trial of XmAb5871, the company's therapeutic antibody for the treatment of autoimmune diseases.

22 Oct 2011

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Johnson & Johnson today announced sales of $16.0 billion for the third quarter of 2011, an increase of 6.8% as compared to the third quarter of 2010. Operational results increased 2.6% and the positive impact of currency was 4.2%. Domestic sales declined 3.7%.

18 Oct 2011

ChemoCentryx commences CCX168 Phase II trial in ANCA-associated vasculitis

ChemoCentryx, Inc., today announced the initiation of a Phase II clinical trial for CCX168, an orally-administered small molecule for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), a disease which can lead to renal and pulmonary failure.

18 Oct 2011

Peanut allergy could be switched off

Now researchers may have discovered how to switch off food allergies. Researchers from Northwestern University found a way to tweak the immune system so that it doesn’t react when foods like peanuts and eggs are encountered – in mice.

12 Oct 2011

ACR celebrates World Arthritis Day with the theme 'Move to Improve'

The American College of Rheumatology joins organizations from around the world in celebrating World Arthritis Day. Held every year on October 12, this year's theme is "Move to Improve" - focusing on using physical activity to combat arthritis and rheumatic diseases - such as osteoarthritis, rheumatoid arthritis, lupus, gout and psoriatic arthritis.

12 Oct 2011

PROLOR receives U.S. patent allowance for CTP-modified interferons

PROLOR Biotech, Inc. today announced that it received a notice of allowance from the U.S. Patent and Trademark Office (PTO) for a patent application covering PROLOR's CTP-modified interferons.

12 Oct 2011

Vertex announces availability of INCIVEK to treat hepatitis C in Canada

Vertex Pharmaceuticals Incorporated announced today that INCIVEK (telaprevir) tablets are now available in Canada for people with genotype 1 chronic hepatitis C with compensated liver disease, including cirrhosis.

11 Oct 2011

Tantalizing glimmers about roles of CCR2 gene, Th17 cell and a missing monocyte

An estimated 1.3 million people in the United States suffer from rheumatoid arthritis. The causes behind this chronic disease — which can exhibit itself as pain, swelling, stiffness, deformation, and loss of function in the joints — have eluded scientists for centuries. A new study by UNC researchers offers tantalizing glimmers about the roles of a gene called CCR2, an immune system cell called Th17 cell, and a missing monocyte.

11 Oct 2011

Researchers identify cellular pathway to potentially block disease-inducing inflammation

Researchers have discovered a cellular pathway that promotes inflammation in diseases like asthma, rheumatoid arthritis, psoriasis, inflammatory bowel disease, and multiple sclerosis. Understanding the details of this pathway may provide opportunities for tailored treatments of inflammatory and autoimmune diseases.

10 Oct 2011

CEL-SCI closes previously announced registered direct offering

CEL-SCI Corporation announced today that it has closed its previously announced registered direct offering for the sale of (i) 13,333,334 shares of its common stock at a price per share of $0.30 and (ii) warrants to purchase up to 12,000,000 shares of CEL-SCI Corporation's common stock at a purchase price of $0.40. The warrants may be exercised at any time prior to October 6, 2014.

7 Oct 2011

Creabilis receives $20 million in Series B funding

Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, inflammation and pain, has raised €15 million ($20 million) in a Series B funding round led by Abbott Biotech Ventures.

4 Oct 2011

La Jolla Institute scientist identifies previously unknown T cell interaction

Most of the time, the immune system is the body's protector, warding off invading viruses and bacteria before they can lead to infection and disease. But in autoimmune diseases, the immune system does an about face, turning on the body and attacking normal cells.

3 Oct 2011

Improper footwear may lead to severe foot pain, impairment and disability in gout patients

New research shows that use of poor footwear is common among patients with gout. According to the study published in Arthritis Care & Research, a peer-reviewed journal of the American College of Rheumatology (ACR), gout patients who make poor footwear choices experienced higher foot-related pain, impairment and disability. Gout patients also reported that comfort, fit, support and cost were the most important factors for selecting footwear.

3 Oct 2011

Express Scripts launches suite of services through HealthBridge Pharma & Biotech

Express Scripts has launched a suite of services for pharmaceutical and biotech companies through HealthBridge Pharma & Biotech, providing a single-solution approach to patient care.

1 Oct 2011

HealthyWomen launches web-based initiative to manage RA

Managing RA: The Strong Woman's Approach, is an online resource designed to educate and empower women living with rheumatoid arthritis (RA), launched today at HealthyWomen.org.

28 Sep 2011

DMARDs appear to be more effective for children with arthritis

Medications known as disease-modifying anti-rheumatic drugs, or DMARDs, appear to be more effective than other treatments for children with arthritis, but there is not enough evidence to support one kind of DMARD over another, according to a new report from HHS' Agency for Healthcare Research and Quality.

28 Sep 2011